VRTX Stock Overview
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRTX from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$447.09 |
| 52 Week High | US$519.88 |
| 52 Week Low | US$377.85 |
| Beta | 0.51 |
| 1 Month Change | -11.20% |
| 3 Month Change | -6.82% |
| 1 Year Change | 0.91% |
| 3 Year Change | 65.56% |
| 5 Year Change | 63.88% |
| Change since IPO | 9,835.33% |
Recent News & Updates
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
May 23
New ALYFTREK And JOURNAVX Will Expand Patient Access
Vertex is set to drive revenue growth by expanding its drug portfolio, notably with ALYFTREK and JOURNAVX, targeting new patient demographics.Recent updates
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
May 23New ALYFTREK And JOURNAVX Will Expand Patient Access
Vertex is set to drive revenue growth by expanding its drug portfolio, notably with ALYFTREK and JOURNAVX, targeting new patient demographics.Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Apr 06Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Mar 06Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Jan 31Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
Jan 14Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Dec 31Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Dec 11Vertex Pharma: Why I Am Buying This Dip
Nov 25Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28
Expanding Treatment Frontiers Boosts Revenue and Market Dominance
Vertex's strategic expansion into new therapeutic areas and successful product launches could deliver significant revenue streams and market penetration.Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22Shareholder Returns
| VRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.0% | 2.6% | 1.2% |
| 1Y | 0.9% | -9.1% | 12.5% |
Return vs Industry: VRTX exceeded the US Biotechs industry which returned -9.1% over the past year.
Return vs Market: VRTX underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| VRTX volatility | |
|---|---|
| VRTX Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VRTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VRTX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 6,100 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VRTX fundamental statistics | |
|---|---|
| Market cap | US$114.30b |
| Earnings (TTM) | -US$988.90m |
| Revenue (TTM) | US$11.10b |
Is VRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRTX income statement (TTM) | |
|---|---|
| Revenue | US$11.10b |
| Cost of Revenue | US$5.21b |
| Gross Profit | US$5.89b |
| Other Expenses | US$6.88b |
| Earnings | -US$988.90m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.85 |
| Gross Margin | 53.09% |
| Net Profit Margin | -8.91% |
| Debt/Equity Ratio | 0% |
How did VRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 11:08 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vertex Pharmaceuticals Incorporated is covered by 66 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |